-
Remdesivir can effectively prevent and treat mers infection
Time of Update: 2020-02-17
The results of animals treated with remdesivir before mers cov infection were good: there was no sign of respiratory disease, compared with the control group, the level of pulmonary virus replication was significantly reduced, and there was no lung injury.
-
Who has passed the pre certification of the first bioequivalent drug - trastuzumab
Time of Update: 2019-12-23
Original: sipian On December 18, 2019, the World Health Organization passed the pre certification of the first trastuzumab bioequivalent drug, which means that this expensive anti
-
First HPV immunotherapy! Inovio / dongfanglue vgx-3100 in the treatment of HPV related anal precancerous lesions phase II clinical completion of patients into the group
Time of Update: 2019-08-20
August 20, 2019 / Biovalley BIOON / -- inovio Pharma, an American vaccine cancer immunotherapy company, recently announced that it has completed the open label of vgx-3100
-
First HPV immunotherapy! Inovio / dongfanglue vgx-3100 in the treatment of HPV related cervical precancerous lesions stage III clinical completion of the patients into the group
Time of Update: 2019-06-28
" Inovio's phase III project is evaluating the efficacy of vgx-3100 in reversing cervical HSIL (high-grade squamous intraepithelial lesions, a direct precursor to cervical cancer) and eliminating HPV infection that causes these lesions.
-
12.16 million yuan invested in R & D! Tenofovir dipivoxil hesco fumarate tablets approved
Time of Update: 2019-04-10
On April 10, hisic announced that its wholly-owned subsidiary Sichuan hisic Pharmaceutical Co., Ltd. had recently received the approval document for drug registration of tenofovir dipivoxil fumarate tablets approved and issued by the State Drug Administration.
-
[drug Kajun] 2019 is a good start, 54 new drugs of category 1 are accepted, Haizheng, Beida, Erjian... And tadalafei generic drugs are coming
Time of Update: 2019-01-28
Highlights: 1
In January 2019, 54 class 1 new drugs of the product specification were accepted; 2
The production of class 1 new drugs of Beida and Haizheng
-
[quick news] on October 18, 2018, researchers developed lithium-ion batteries with specific dimensions for 3D printing
Time of Update: 2018-10-18
Https://www.engadget.com/2018/10/17/research-3d-printed-lithium-ion-batteries/ recently, a paper published by nature Online reported a data set, revealing the relationship between specific mutations and drug sensitivity in patients with acute myeloid leukemia (AML).
-
In 2018, which new anticancer drugs will be launched in China
Time of Update: 2018-03-02
On December 20, 2017, FDA approved the combination of patozumab, trastuzumab and chemotherapy for adjuvant treatment of early HER2 + breast cancer patients with high risk of recurrence.
-
[week king] we're going to attack the policy of heavyweight, the hot spots in the pharmaceutical industry, and the frontier news of new drug research and development
Time of Update: 2017-11-20
(news source: yaozhi.com) recently, Sangamo therapeutics announced that its first patient in the research and development of sb-913 has completed the drug administration.
-
Rational reform of new drug research and development
Time of Update: 2017-09-05
[China Pharmaceutical network industry trends] China's new drug R & D is in its infancy
Because most local pharmaceutical enterprises are still in the stage
-
Christmas Day gift: AstraZeneca's ovarian cancer drug lynparza won two markets in Europe and the United States at the same time
Time of Update: 2014-12-22
Source: Bio Valley December 21, 2014 / Bio Valley bio on / -- although it was rejected by the FDA expert committee, the FDA did not hesitate to accelerate the approval
-
AstraZeneca's $2 billion ovarian cancer drug lynparza has been approved by the European Union
Time of Update: 2014-12-19
The European Commission (EC) has approved lynparza as a single drug therapy for the maintenance treatment of platinum sensitive recurrent BRCA mutant ovarian cancer in adult patients.
-
FDA grants priority to olaparib
Time of Update: 2014-05-05
At the same time, AstraZeneca launched olaparib's phase III solo project in September 2013 to investigate the PFS benefits of olaparib as a single drug therapy for the maintenance treatment of patients with BRCA mutant platinum sensitive ovarian cancer.
-
Prospects for new drug research and development in 2014
Time of Update: 2013-12-31
Source: which new drugs are under development in the coming year of 2014 in China Medical Journal December 31, 2013? Cancer, heart failure, obesity and diabetes, hepatitis C
-
Analysis on the development depth of the market of antitumor drugs in Guangdong Province
Time of Update: 2013-09-24
From the perspective of enterprise competition, in recent years, Shenzhen Wanle Pharmaceutical Co., Ltd. ranked first with more than 90% market share, becoming the leading enterprise of this kind of drugs.
